20:33:47 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-10-23 Kvartalsrapport 2024-Q3
2024-07-15 Kvartalsrapport 2024-Q2
2024-05-10 Ordinarie utdelning ALIF B 0.50 SEK
2024-05-08 Årsstämma 2024
2024-04-24 Kvartalsrapport 2024-Q1
2024-02-02 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-14 Kvartalsrapport 2023-Q2
2023-05-05 Ordinarie utdelning ALIF B 1.20 SEK
2023-05-04 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-02-02 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-07-15 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning ALIF B 2.00 SEK
2022-05-05 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-04 Bokslutskommuniké 2021
2021-10-22 Kvartalsrapport 2021-Q3
2021-07-15 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning ALIF B 1.50 SEK
2021-05-05 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-03 Bokslutskommuniké 2020
2020-11-20 Bonusutdelning ALIF B 0.5
2020-11-19 Extra Bolagsstämma 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-07-17 Kvartalsrapport 2020-Q2
2020-05-27 Split ALIF B 1:4
2020-05-08 Ordinarie utdelning ALIF B 0.00 SEK
2020-05-07 Årsstämma 2020
2020-04-28 Kvartalsrapport 2020-Q1
2020-02-06 Bokslutskommuniké 2019
2019-11-07 Kvartalsrapport 2019-Q3
2019-07-12 Kvartalsrapport 2019-Q2
2019-05-10 Ordinarie utdelning ALIF B 2.20 SEK
2019-05-09 Kvartalsrapport 2019-Q1
2019-05-09 Årsstämma 2019
2019-02-12 Bokslutskommuniké 2018
2018-12-20 Extra Bolagsstämma 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-07-13 Kvartalsrapport 2018-Q2
2018-06-01 Ordinarie utdelning ALIF B 2.20 SEK
2018-05-31 Årsstämma 2018
2018-04-27 Kvartalsrapport 2018-Q1
2018-02-13 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-07-17 Kvartalsrapport 2017-Q2
2017-05-30 Ordinarie utdelning ALIF B 1.50 SEK
2017-05-29 Årsstämma 2017
2017-04-28 Kvartalsrapport 2017-Q1
2017-02-16 Bokslutskommuniké 2016
2016-10-27 Kvartalsrapport 2016-Q3
2016-09-02 Ordinarie utdelning ALIF B 0.00 SEK
2016-09-01 Årsstämma 2016
2016-07-15 Kvartalsrapport 2016-Q2

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
AddLife är en koncern med verksamhet inom life-science sektorn. Inom koncernen återfinns specialisering främst mot diagnostik, medicinteknik och biomedicinsk forskning. Verksamhet innehas främst i Norden och Baltikum med kunder inom vård och omsorg, samt forskningsinstitut. Addlife bildades under 2015 vid en avknoppning ur Addtech koncernen. Bolaget har sitt huvudkontor i Stockholm.
2019-02-21 12:30:00

AddLife AB's (publ) ("AddLife" or the "Company") rights issue with preferential rights for the Company's shareholders has been fully subscribed. The subscription period for the rights issue ended on 15 February 2019. The final count shows that 142,901 A-shares and 3,357,585 B-shares, corresponding to approximately 99.3 percent of the offered shares, were subscribed for with subscription rights.

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, HONG KONG, SWITZERLAND, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES BESIDES THOSE REQUIRED BY SWEDISH LAW. ADDITIONAL RESTRICTIONS ARE APPLICABLE, SEE IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE
 
The remaining 1,637 A-shares and 24,636 B-shares that were not subscribed for with subscription rights have been allocated to those who have applied for subscription of shares without subscription rights in accordance with the principles described in the prospectus. Allotment of shares not subscribed for with subscription rights has only been made to those who have subscribed for shares with subsidiary preferential rights. Interest in the rights issue has been high and as a result the rights issue was oversubscribed by 68 percent.
Notification regarding allotment of shares which have been subscribed for without subscription rights will be distributed on or about 21 February 2019 by settlement note to subscribers or nominees. Subscribed and allotted new shares shall be paid in cash on the settlement day in accordance with the instructions on the settlement note, on or around 26 February 2019. Nominee registered shareholders will receive notification regarding allotment of shares in accordance with the respective nominee's procedures.
Through the rights issue AddLife will receive proceeds amounting to approximately SEK 501 million before deduction of issue costs. As a result of the rights issue, AddLife's share capital will increase by SEK 7,184,142 to SEK 58,309,340. The total number of A-shares will increase by 144,538 shares and B-shares will increase by 3,382,221 shares to a total of 28,624,573 shares, of which 1,156,304 are A-shares and 27,468,269 are B-shares.
New A-shares and B-shares subscribed for with subscription rights are expected to be registered with the Swedish Companies Registration Office on or about 22 February 2019 and trading in the new class B shares on Nasdaq Stockholm is expected to commence on or about 26 February 2019. The class B shares subscribed for without subscription rights are expected to start trading on Nasdaq Stockholm on or about 5 March 2019.
Adviser for the rights issue
Handelsbanken Capital Markets is financial adviser in connection with the rights issue. Advokatfirman Delphi is legal adviser.
Stockholm, 21 February 2019
AddLife AB (publ)

For further information, please contact:
Kristina Willgård, CEO, kristina.willgard@add.life,+46 (0)705 10 12 23
Martin Almgren, CFO, martin.almgren@add.life,+46 (0)702 28 15 45
IMPORTANT INFORMATION
The information in this press release shall not constitute an offer to acquire, subscribe for or otherwise trade in shares or other securities in AddLife. No action has been taken and measures will not be taken to permit an offer to the public in any jurisdictions other than Sweden.
The information in this press release may not be released, published or distributed, directly or indirectly, in or into the United States (including its territories and provinces, every state in the United States and the District of Columbia (the "US")), Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore or South Africa or at any other person where participation would require an additional prospectus, registration or other measures than those that follow by Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws.
No action has been taken or will be taken by AddLife that would permit an offer to the public in any country other than Sweden. Neither subscription rights in the offer, paid and subscribed shares nor new shares subscribed for in the offer have been, nor will be, registered under the United States Securities Act of 1933 as amended (the "Securities Act"). Securities may not be offered or sold, directly or indirectly, in or into the US, or to persons domiciled there, except pursuant to an applicable exemption from the registration requirements of the Securities Act.

AddLife is an independent player in the Life Science industry that offers high-quality products, services and advice to both the private and public sector, mainly in the Nordic region. AddLife has about 900 employees in some 40 operating subsidiaries. The group currently has net sales of around SEK 2.5 billion. The AddLife share is listed on Nasdaq Stockholm.

This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 21 February 2019 at 12.30 p.m. (CET).